Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Orer, H. S.Nomak, G.Oksuzoglu, B.Senturk, R.Eralp, Y.Yumuk, F.Nomak, H.Sanyal, R.2023-02-212023-02-212022-01-0110.1016/j.annonc.2022.07.1876https://hdl.handle.net/11443/2335http://dx.doi.org/10.1016/j.annonc.2022.07.1876Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)ArticleWOS:000866211601462